Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Experimental Peritoneal Dialysis · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Experimental Peritoneal Dialysis Solution | DRUG | - |
Inclusion Criteria: * Patients who have given written informed consent after the nature of the study has been explained. * Patients who are at least 18 years of age. * Patients who have been treated with CAPD using specific solutions for at least 60 days before the baseline visit. Exclusion Criter...
Experimental Peritoneal Dialysis is an investigational small molecule being studied for the treatment of End Stage Renal Disease. It is a solution used in peritoneal dialysis, a method of filtering waste from the blood when the kidneys no longer function adequately. The drug is currently in Phase 3 clinical development.
Experimental Peritoneal Dialysis is being developed by Baxter International Inc., a company traded on the New York Stock Exchange under the ticker BAX. Baxter is conducting clinical research to evaluate the efficacy and safety of this experimental solution for peritoneal dialysis in patients with End Stage Renal Disease.
Experimental Peritoneal Dialysis is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 3 trial has been completed to evaluate its efficacy and safety in patients with End Stage Renal Disease.
Experimental Peritoneal Dialysis has one completed Phase 3 clinical trial, registered as NCT00214721. The study, titled "A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal Dialysis," enrolled 120 participants with End Stage Renal Disease in Canada. The trial was completed and included adult patients aged 18 years and older.
The Phase 3 clinical trial of Experimental Peritoneal Dialysis, NCT00214721, was a randomized study. However, it was an uncontrolled trial, meaning there was no control group receiving a comparator treatment. The study was not double-blinded and enrolled 120 patients with End Stage Renal Disease.